Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00255450 · ClinicalTrials.gov registry record · Phase 3
A Crossover Safety Study of Ferumoxytol Versus Placebo
A Phase 3 study, sponsored by AMAG Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 750
- Enrollment target
NCT00255450 is a Phase 3 study that has completed, run by AMAG Pharmaceuticals. The registered enrollment target is 750 participants.
The verdict
NCT00255450, a Phase 3 study, has completed, sponsored by AMAG Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 750 participants
- Enrollment target
Study Summary
This crossover safety study will evaluate the safety of a single dose of ferumoxytol compared to placebo in patients with chronic kidney disease.
Interventions
- DRUG ferumoxytol or placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00255450
The ClinicalTrials.gov registry entry for NCT00255450 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AMAG Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ferumoxytol or placebo is the first listed.
NCT00255450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00255450 about?
NCT00255450 is a clinical study titled "A Crossover Safety Study of Ferumoxytol Versus Placebo". This crossover safety study will evaluate the safety of a single dose of ferumoxytol compared to placebo in patients with chronic kidney disease.
What is the current status of trial NCT00255450?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 750 participants. The study started on 2005-01. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00255450?
The interventions under investigation include: ferumoxytol or placebo (DRUG).
Who is sponsoring clinical trial NCT00255450?
This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.